# A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

> **NCT01171651** · PHASE2 · COMPLETED · sponsor: **Jennerex Biotherapeutics** · enrollment: 25 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** JX-594 followed by sorafenib

## Key facts

- **NCT ID:** NCT01171651
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2013-02
- **Final completion:** 2015-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171651, "A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01171651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*